Equibles does not estimate personal net worth.
Get an email with a short summary when TransMedics Group, Inc. publishes a filing, an earnings call transcript or a press release.
Get TMDX alertsGerardo Hernandez is recorded as CFO at TransMedics Group, Inc. (TMDX). The newest filing on record that lists Gerardo Hernandez as CFO at TransMedics Group, Inc. (TMDX) is dated April 10, 2026. TransMedics Group, Inc. reported in an 8-K filed December 2, 2024 that Gerardo Hernandez was appointed Chief Financial Officer and Treasurer, effective December 2, 2024. The proxy statement of TransMedics Group, Inc. reports total compensation of $1,570,572 for Gerardo Hernandez in fiscal 2025, including a base salary of $488,462. Disclosed compensation is on record for 2 fiscal years. Gerardo Hernandez has spoken on 6 earnings calls and 2 other investor events across 1 company, most recently for TransMedics Group, Inc. on September 14, 2026. TransMedics Group, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at TransMedics Group, Inc. includes Waleed Hassanein (CEO and Board Member), Fernando Araujo (CFO), Anil Ranganath (General Counsel) and 7 others.
“On November 26, 2024, the Board of Directors (the "Board") of TransMedics Group, Inc. (the "Company") appointed Gerardo Hernandez, as Chief Financial Officer and Treasurer, effective as of December 2, 2024.”
“It's at or approaching 30% corresponds to what we are seeing today. The 30% is indeed the operating margin that I believe the company has delivered. Actually, we have some upside potentially there.”
“It's an at or approaching 30% corresponds to what we are seeing today. The 30% is indeed the operating margin that I believe the company has delivered. Actually, we have some upside potentially there.”
“I am pleased to share Transmedic's first quarter 2026 results. Please note that a supplemental slide presentation with additional details is available in the Investor section of our website.”
“I am pleased to share TransMedics' Fourth Quarter 2025 Results. Please note that a supplemental slide presentation with additional details is available on the Investors section of our website.”
“I am pleased to be here to discuss TransMedics' third quarter results. Please note that a supplemental slide presentation with additional details on our third quarter 2025 results is available in the Investors section of our website.”
Start not stated–present
Last confirmed April 10, 2026
Medical Devices · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | TransMedics Group, Inc. (TMDX) | Chief Financial Officer | $488,462 | $1,570,572 |
| 2024 | TransMedics Group, Inc. (TMDX) | Chief Financial Officer | $17,308 | $1,757,472 |
